The bitter side of sweet: The role of Galectin-9 in immunopathogenesis of viral infections

Reviews in Medical Virology

Volumn 25, Issue 3, 2015, Pages 175-186

  Merani, Shahzma ^a   Chen, Wenna ^a   Elahi, Shokrollah ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; VACCINE; GALECTIN; LGALS9 PROTEIN, HUMAN;

ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENGUE; DENGUE VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; VIRUS INFECTION; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; VIROLOGY; VIRUS DISEASES;

ANIMALS; GALECTINS; HUMANS; IMMUNOMODULATION; VIRUS DISEASES;

EID: 84928755858     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1832     Document Type: Article

References (90)

1. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Introduction to galectins. Glycoconjugate Journal 2004; 19: 433-440. DOI:10.1023/B:GLYC.0000014072.34840.04.
2. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nature Reviews Immunology 2009; 9: 338-352. DOI:10.1038/nri2536.
3. Elahi S, Niki T, Hirashima M, Horton H. Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood 2012; 119: 4192-4204. DOI:10.1182/blood-2011-11-389585.
4. Sato S, St-Pierre C, Bhaumik P, Nieminen J. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunological Reviews 2009; 230: 172-187. DOI:10.1111/j.1600-065X.2009.00790.x.
5. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nature Immunology 2008; 9: 593-601. DOI:10.1038/ni.f.203.
6. Vasta GR. Roles of galectins in infection. Nature Reviews Microbiology 2009; 7: 424-438. DOI:10.1038/nrmicro2146.
7. Matsumoto R, Matsumoto H, Seki M, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. Journal of Biological Chemistry 1998; 273: 16976-16984.
8. Li Y, Feng J, Geng S, et al. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Molecular Immunology 2011; 48: 670-677. DOI: S0161-5890(10)00646-2 [pii] 10.1016/j.molimm.2010.11.011
9. Hirashima M, Kashio Y, Nishi N, et al. Galectin-9 in physiological and pathological conditions. Glycoconjugate Journal 2004; 19: 593-600. DOI: 10.1023/B:GLYC.0000014090.63206.2f 5256171 [pii]
10. Elahi S, Dinges WL, Lejarcegui N, et al. Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression. Nature Medicine 2011; 17: 989-995. DOI: nm.2422 [pii] 10.1038/nm.2422
11. Hirashima M. Galectin, especially galectin-9/ecalectin. Nihon Rinsho 2005; 63(Suppl 8): 133-136.
12. Irie A, Yamauchi A, Kontani K, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clinical Cancer Research 2005; 11: 2962-2968. DOI: 11/8/2962 [pii] 10.1158/1078-0432.CCR-04-0861
13. Jayaraman P, Sada-Ovalle I, Beladi S, et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. Journal of Experimental Medicine 2010; 207: 2343-2354. DOI: jem.20100687 [pii] 10.1084/jem.20100687
14. Kashio Y, Nakamura K, Abedin MJ, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. Journal of Immunology 2003; 170: 3631-3636.
15. Kobayashi T, Kuroda J, Ashihara E, et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 2010; 24: 843-850. DOI: leu201025 [pii] 10.1038/leu.2010.25
16. Nagahara K, Arikawa T, Oomizu S, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. Journal of Immunology 2008; 181: 7660-7669. DOI: 181/11/7660 [pii]
17. Thijssen VL, Griffioen AW. Galectin-1 and galectin-9 in angiogenesis: a sweet couple. Glycobiology 2014. DOI:10.1093/glycob/cwu048.
18. Thijssen VL, Hulsmans S, Griffioen AW. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. American Journal of Pathology 2008; 172: 545-553. DOI: S0002-9440(10)61818-4 [pii] 10.2353/ajpath.2008.070938
19. Fujihara S, Mori H, Kobara H, et al. Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discovery 2013; 7: 130-137.
20. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of Galectin-9 in human disease. Medicinal Research Reviews 2011. DOI:10.1002/med.20249.
21. Chen X, Song CH, Liu ZQ, et al. Intestinal epithelial cells express galectin-9 in patients with food allergy that plays a critical role in sustaining allergic status in mouse intestine. Allergy 2011; 66: 1038-1046. DOI:10.1111/j.1398-9995.2011.02585.x.
22. Hirashima M. Ecalectin/galectin-9, a novel eosinophil chemoattractant: its function and production. International Archives of Allergy and Immunology 2000; 122(Suppl 1): 6-9. DOI: 53623 [pii]
23. Imaizumi T, Yoshida H, Nishi N, et al. Double-stranded RNA induces galectin-9 in vascular endothelial cells: involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology 2007; 17: 12C-15C. DOI: cwm045 [pii] 10.1093/glycob/cwm045
24. Ishikawa A, Imaizumi T, Yoshida H, et al. Double-stranded RNA enhances the expression of galectin-9 in vascular endothelial cells. Immunology and Cell Biology 2004; 82: 410-414. DOI: 10.1111/j.0818-9641.2004.01248.x ICB1248 [pii]
25. Mengshol JA, Golden-Mason L, Arikawa T, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 2010; 5: e9504. DOI:10.1371/journal.pone.0009504.
26. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology 2005; 6: 1245-1252. DOI: ni1271 [pii] 10.1038/ni1271
27. Bi S, Hong PW, Lee B, Baum LG. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T cell migration and HIV entry. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 10650-10655. DOI: 1017954108 [pii] 10.1073/pnas.1017954108
28. Niki T, Tsutsui S, Hirose S, et al. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. Journal of Biological Chemistry 2009; 284: 32344-32352. DOI: M109.035196 [pii] 10.1074/jbc.M109.035196
29. Madireddi S, Eun SY, Lee SW, et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. Journal of Experimental Medicine 2014; 211: 1433-1448. DOI:10.1084/jem.20132687.
30. Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y. Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochemical and Biophysical Research Communications 2010; 394: 317-322. DOI: S0006-291X(10)00419-5 [pii] 10.1016/j.bbrc.2010.02.175
31. Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007; 318: 1141-1143. DOI:10.1126/science.1148536.
32. Chou FC, Shieh SJ, Sytwu HK. Attenuation of Th1 response through galectin-9 and T cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. European Journal of Immunology 2009; 39: 2403-2411. DOI:10.1002/eji.200839177.
33. Bi S, Earl LA, Jacobs L, Baum LG. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. Journal of Biological Chemistry 2008; 283: 12248-12258. DOI: M800523200 [pii] 10.1074/jbc.M800523200
34. Lu LH, Nakagawa R, Kashio Y, et al. Characterization of galectin-9-induced death of Jurkat T cells. Journal of Biochemistry 2007; 141: 157-172. DOI: mvm019 [pii] 10.1093/jb/mvm019
35. Niwa H, Satoh T, Matsushima Y, et al. Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Clinical Immunology 2009; 132: 184-194. DOI: S1521-6616(09)00659-7 [pii] 10.1016/j.clim.2009.04.012
36. Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clinical Immunology 2008; 127: 78-88. DOI: S1521-6616(08)00008-9 [pii] 10.1016/j.clim.2008.01.006
37. Wu C, Thalhamer T, Franca RF, et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 2014; 41: 270-282. DOI:10.1016/j.immuni.2014.06.011.
38. Salek-Ardakani S, Croft M. Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T cell immunity. Journal of Interferon and Cytokine Research 2010; 30: 205-218. DOI:10.1089/jir.2010.0026.
39. Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. T cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunological Reviews 2011; 244: 197-217. DOI:10.1111/j.1600-065X.2011.01063.x.
40. Asakura H, Kashio Y, Nakamura K, et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. Journal of Immunology 2002; 169: 5912-5918.
41. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-541. DOI:10.1038/415536a.
42. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nature Immunology 2003; 4: 1102-1110. DOI:10.1038/ni988.
43. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011; 21: 1258-1265. DOI: cwq214 [pii] 10.1093/glycob/cwq214
44. Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015; 517: 386-390. DOI:10.1038/nature13848.
45. Sharma S, Sundararajan A, Suryawanshi A, et al. T cell immunoglobulin and mucin protein-3 (Tim-3)/galectin-9 interaction regulates influenza a virus-specific humoral and CD8 T cell responses. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 19001-19006. DOI: Doi 10.1073/Pnas.1107087108
46. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. Journal of Experimental Medicine 2008; 205: 2763-2779. DOI: jem.20081398 [pii] 10.1084/jem.20081398
47. Chagan-Yasutan H, Shiratori B, Siddiqi UR, et al. The increase of plasma galectin-9 in a patient with insulin allergy: a case report. Clin Mol Allergy 2010; 8: 12. DOI: 1476-7961-8-12 [pii] 10.1186/1476-7961-8-12
48. Tandon R, Chew GM, Byron MM, et al. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Research and Human Retroviruses 2014. DOI:10.1089/AID.2014.0004.
49. Katoh S, Ikeda M, Shimizu H, et al. Increased levels of plasma galectin-9 in patients with influenza virus infection. Tohoku Journal of Experimental Medicine 2014; 232: 263-267.
50. Kared H, Fabre T, Bedard N, Bruneau J, Shoukry NH. Galectin-9 and IL-21 mediate cross-regulation between Th17 and treg cells during acute hepatitis C. Plos Pathogens 2013; 9. DOI: Artn E1003422 Doi 10.1371/Journal.Ppat.1003422
51. Reddy PB, Sehrawat S, Suryawanshi A, et al. Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency. Journal of Immunology 2011; 187: 5745-5755. DOI:10.4049/jimmunol.1102105.
52. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathogen 2010; 6: e1000882. DOI:10.1371/journal.ppat.1000882.
53. Shim JA, Park S, Lee ES, Niki T, Hirashima M, Sohn S. Galectin-9 ameliorates herpes simplex virus-induced inflammation through apoptosis. Immunobiology 2012; 217: 657-666. DOI: Doi 10.1016/J.Imbio.2011.11.002
54. McSharry BP, Forbes SK, Cao JZ, et al. Human cytomegalovirus upregulates expression of the lectin galectin 9 via induction of beta interferon. Journal of Virology 2014; 88: 10990-10994. DOI:10.1128/JVI.01259-14.
55. Nebbia G, Peppa D, Schurich A, et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. Plos One 2012; 7. DOI: ARTN e47648 DOI 10.1371/journal.pone.0047648
56. Chagan-Yasutan H, Ndhlovu LC, Lacuesta TL, et al. Galectin-9 plasma levels reflect adverse hematological and immunological features in acute dengue virus infection. Journal of Clinical Virology 2013; 58: 635-640. DOI:10.1016/j.jcv.2013.10.022.
57. Chagan-Yasutan H, Saitoh H, Ashino Y, et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. Tohoku Journal of Experimental Medicine 2009; 218: 285-292. DOI: JST.JSTAGE/tjem/218.285 [pii]
58. Chen H, Li C, Huang J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. Journal of Clinical Investigation 2011; 121: 1549-1560. DOI: 44539 [pii] 10.1172/JCI44539
59. Bergamaschi A, David A, Le Rouzic E, Nisole S, Barre-Sinoussi F, Pancino G. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. Journal of Virology 2009; 83: 12253-12265. DOI: JVI.01395-09 [pii] 10.1128/JVI.01395-09
60. Wang D, de la Fuente C, Deng L, et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. Journal of Virology 2001; 75: 7266-7279. DOI:10.1128/JVI.75.16.7266-7279.2001.
61. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. Journal of Clinical Investigation 2007; 117: 473-481. DOI:10.1172/JCI28971.
62. Bieniasz PD. An intrinsic host defense against HIV-1 integration? Journal of Clinical Investigation 2007; 117: 302-304. DOI:10.1172/JCI31290.
63. Chabot S, Kashio Y, Seki M, et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 2002; 12: 111-118.
64. Saitoh H, Ashino Y, Chagan-Yasutan H, Niki T, Hirashima M, Hattori T. Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy. Tohoku Journal of Experimental Medicine 2012; 228: 157-161.
65. Golden-Mason L, McMahan RH, Strong M, et al. Galectin-9 functionally impairs natural killer cells in humans and mice. Journal of Virology 2013; 87: 4835-4845. DOI:10.1128/JVI.01085-12.
66. Golden-Mason L, Palmer BE, Kassam N, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. Journal of Virology 2009; 83: 9122-9130. DOI: JVI.00639-09 [pii] 10.1128/JVI.00639-09
67. Gleason MK, Lenvik TR, McCullar V, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012; 119: 3064-3072. DOI:10.1182/blood-2011-06-360321.
68. Ndhlovu LC, Lopez-Verges S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119: 3734-3743. DOI:10.1182/blood-2011-11-392951.
69. Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nature Reviews Immunology 2010; 10: 514-526. DOI:10.1038/nri2802.
70. Elahi S, Horton H. Association of HLA-alleles with the immune regulation of chronic viral infections. International Journal of Biochemistry and Cell Biology 2012; 44: 1361-1365. DOI:10.1016/j.biocel.2012.05.003.
71. Kuchroo VK, Meyers JH, Umetsu DT, DeKruyff RH. TIM family of genes in immunity and tolerance. Advances in Immunology 2006; 91: 227-249. DOI:10.1016/S0065-2776(06)91006-2.
72. Sehrawat S, Suryawanshi A, Hirashima M, Rouse BT. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. Journal of Immunology 2009; 182: 3191-3201. DOI: 182/5/3191 [pii] 10.4049/jimmunol.0803673
73. Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008; 29: 362-371. DOI:10.1016/j.immuni.2008.08.005.
74. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nature Immunology 2005; 6: 353-360. DOI:10.1038/ni1181.
75. Teijaro JR. The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Current Topics in Microbiology and Immunology 2015; 386: 3-22. DOI:10.1007/82_2014_411.
76. Sangster MY, Riberdy JM, Gonzalez M, Topham DJ, Baumgarth N, Doherty PC. An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions. Journal of Experimental Medicine 2003; 198: 1011-1021. DOI:10.1084/jem.20021745.
77. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. Journal of Clinical Investigation 1998; 101: 1500-1508. DOI:10.1172/jci1758.
78. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008; 322: 268-271. DOI:10.1126/science.1164164.
79. Allen SJ, Hamrah P, Gate D, et al. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. Journal of Virology 2011; 85: 4184-4197. DOI:10.1128/JVI.02290-10.
80. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. Journal of Experimental Medicine 2003; 198: 889-901. DOI:10.1084/jem.20030171.
81. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496: 504-507. DOI:10.1038/nature12060.
82. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clinical Microbiology Reviews 2009; 22: 564-581. DOI:10.1128/cmr.00035-09.
83. Slobedman B, Cao JZ, Avdic S, et al. Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiology 2010; 5: 883-900. DOI:10.2217/fmb.10.58.
84. Leaman DW, Chawla-Sarkar M, Jacobs B, et al. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. Journal of Interferon and Cytokine Research 2003; 23: 745-756. DOI:10.1089/107999003772084860.
85. Ndhlovu ZM, Chibnik LB, Proudfoot J, et al. High-dimensional immunomonitoring models of HIV-1-specific CD8 T cell responses accurately identify subjects achieving spontaneous viral control. Blood 2013; 121: 801-811. DOI:10.1182/blood-2012-06-436295.
86. Nebbia G, Peppa D, Schurich A, et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012; 7: e47648. DOI:10.1371/journal.pone.0047648.
87. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathogen 2013; 9: e1003490. DOI:10.1371/journal.ppat.1003490.
88. Callendret B, Walker C. A siege of hepatitis: immune boost for viral hepatitis. Nature Medicine 2011; 17: 252-253. DOI:10.1038/nm0311-252.
89. Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology 2014; 59: 1351-1365. DOI:10.1002/hep.26938.
90. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-1433. DOI:10.1126/science.342.6165.1432.